Form 4 Filing for CRISPR Therapeutics AG

This filing reports a stock option grant to Harold Edward Fleming, a director at CRISPR Therapeutics AG. The grant, dated June 5, 2026, includes 13,000 stock options for Common Shares with a purchase price of $51.84 per share. The options are exercisable upon vesting, which occurs in 12 equal monthly installments starting June 30, 2026, and will fully vest by June 5, 2027, or the 2027 Annual Meeting, whichever comes first. The options expire on June 5, 2036. This transaction is classified as an acquisition of securities by an insider.